Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation vs continuation of anti-TNF therapy in ulcerative colitis remission
2016-001409-18Phase 4Active
- Sponsor
- Helse Møre og Romsdal
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab, adalimumab and golimumab in autoimmune colitis (2 arms), sponsored by Helse Møre og Romsdal. Primary endpoint: Proportion of patients in sustained clinical remission with mucosal healing at 2 years. Started May 2016; status: active.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-001409-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001409-18.